CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 70 enrolled
Drug / intervention
Tezepelumab +1 moredrug
Likely dose
Tezepelumab 210 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05062759
NCT05062759Phase 3Completed
CompareCT.gov

A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Potential Effect of Tezepelumab on the Humoral Immune Response to Seasonal Quadrivalent Influenza Vaccination in Adolescent and Young Adult Participants With Moderate to Severe Asthma (VECTOR)

AstraZeneca·interventional·Posted Sep 30, 2021·Updated Jun 22, 2023

In Brief

A Phase 3 clinical trial evaluating Tezepelumab and Placebo for Moderate to Severe Asthma. Completed, enrolled 70 participants across 15 sites.

Detailed Summary

This is a Phase 3b, multicenter, randomized, double-blind, parallel group, placebo-controlled study designed to investigate the potential effect of tezepelumab (210 mg subcutaneous \[SC\] every 4 weeks \[Q4W\]) on antibody responses following seasonal quadrivalent influenza virus vaccination in the fall/winter 2021-2022 in the USA.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsModerate to Severe Asthma
CountriesUnited States
CollaboratorsAmgen

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedSep 30, 2021
Enrollment StartAug 23, 2021
Primary CompletionMar 21, 2022
Study CompletionJul 18, 2022
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 4.8 years ago

Interventions

Tezepelumabdrug

210 mg SC injection Q4W.

Placebodrug

SC injection Q4W.